Latest News
BrightFocus-funded research offers the potential to restore vision loss due to glaucoma using cell replacement therapy.
Researchers have identified a new gene region in people of African descent that reduces Alzheimer's disease risk—highlighting the importance of diversity and inclusion of all populations in research.
A recent study reveals that an anti-inflammatory drug approved to treat certain autoimmune diseases can counteract a protein in the body that’s linked to age-related macular degeneration. These findings may lead to a new treatment option for the disease.
A BrightFocus Foundation-funded study found that even moderate alcohol use can cause changes in the brain that may accelerate Alzheimer’s disease, shedding new light on a possible modifiable risk factor for dementia.
BrightFocus-funded research offers new evidence of the importance of tau in the prediction of Alzheimer’s disease which could lead to ways to delay—or even stop—the disease from progressing.
Read about some of the ways BrightFocus Foundation is taking action to reduce health disparities and inequities among underrepresented communities and better meet the precise health needs of these populations.
BrightFocus Foundation celebrates the U.S. Food and Drug Administration’s approval of Syfovre (pegcetacoplan injection), the first-ever treatment to slow the progression of vision loss from geographic atrophy, an advanced form of dry age-related macular degeneration and a leading cause of blindness.
Led by a BrightFocus grantee, a research team has developed a new marker of Alzheimer’s disease neurodegeneration in the blood, paving the way for a more accurate blood test to detect Alzheimer’s disease.
In recognition of Macular Degeneration Awareness Month this February, BrightFocus Foundation, a nonprofit dedicated to ending diseases of mind and sight, is offering a variety of free educational resources to help individuals with macular degeneration and their loved ones navigate the disease.
Using a molecule found in green tea, an Alzheimer's Disease Research-funded team of biochemists has identified new molecules that can destroy protein tangles in the brain linked to Alzheimer's and related brain diseases.
